Skip to main content

Compare Stocks

Date Range: 

 Black Diamond TherapeuticsVaxcyteSutro BiopharmaTCR2 TherapeuticsTaysha Gene Therapies
SymbolNASDAQ:BDTXNASDAQ:PCVXNASDAQ:STRONASDAQ:TCRRNASDAQ:TSHA
Price Information
Current Price$26.56$19.09$18.83$19.01$20.92
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.71.31.61.8
Analysis Score3.53.52.53.53.5
Community Score2.72.92.42.64.0
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.70.8
Earnings & Valuation Score0.00.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$51.50$48.00$24.60$43.29$43.92
% Upside from Price Target93.90% upside151.44% upside30.64% upside127.70% upside109.93% upside
Trade Information
Market Cap$960.46 million$980.37 million$868.31 million$724.98 million$791.13 million
BetaN/AN/A0.82.13N/A
Average Volume414,149369,527509,733503,17585,356
Sales & Book Value
Annual RevenueN/AN/A$42.74 millionN/AN/A
Price / SalesN/AN/A20.32N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($1.44) per shareN/A$4.24 per share$6.68 per shareN/A
Price / BookN/AN/A4.44N/AN/A
Profitability
Net Income$-35,260,000.00$-50,270,000.00$-55,740,000.00$-47,600,000.00N/A
EPS($16.99)N/A($2.43)($4.62)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A27.60%N/AN/A
Return on Equity (ROE)-22.28%N/A-41.86%-35.51%N/A
Return on Assets (ROA)-17.91%N/A-29.50%-34.02%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.10%N/AN/A
Current Ratio29.67%10.12%9.77%32.38%24.02%
Quick Ratio29.66%10.12%9.77%32.38%24.02%
Ownership Information
Institutional Ownership Percentage65.78%74.08%78.80%82.05%42.19%
Insider Ownership PercentageN/AN/A28.90%27.99%N/A
Miscellaneous
Employees695819511838
Shares Outstanding36.16 million51.36 million46.11 million38.14 million37.82 million
Next Earnings Date8/10/2021 (Estimated)8/11/2021 (Estimated)8/5/2021 (Estimated)N/A8/10/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Taysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume IncreaseTaysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume Increase
americanbankingnews.com - May 13 at 11:54 AM
Analysts Issue Forecasts for Taysha Gene Therapies, Inc.s Q1 2021 Earnings (NASDAQ:TSHA)Analysts Issue Forecasts for Taysha Gene Therapies, Inc.'s Q1 2021 Earnings (NASDAQ:TSHA)
americanbankingnews.com - May 13 at 8:22 AM
Taysha Gene Therapies (TSHA) CEO RA Session II on Q1 2021 Results - Earnings Call TranscriptTaysha Gene Therapies' (TSHA) CEO RA Session II on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 7:11 PM
Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare ConferencesTaysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
finance.yahoo.com - May 12 at 7:11 PM
Taysha Gene Therapies (NASDAQ:TSHA) Releases  Earnings Results, Misses Expectations By $0.33 EPSTaysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Misses Expectations By $0.33 EPS
americanbankingnews.com - May 12 at 2:38 PM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $20.52Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $20.52
americanbankingnews.com - May 12 at 10:58 AM
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate UpdateTaysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 11 at 9:45 AM
Taysha Gene Therapies Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021Taysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021
finance.yahoo.com - May 10 at 7:24 PM
Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-ReTaysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Re
us.acrofan.com - May 10 at 9:23 AM
Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed JournalTaysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal
finance.yahoo.com - May 10 at 9:23 AM
Reviewing Taysha Gene Therapies (NASDAQ:TSHA) & Vir Biotechnology (NASDAQ:VIR)Reviewing Taysha Gene Therapies (NASDAQ:TSHA) & Vir Biotechnology (NASDAQ:VIR)
americanbankingnews.com - May 7 at 1:38 AM
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7.3%Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7.3%
americanbankingnews.com - May 6 at 2:52 PM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $22.68Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $22.68
americanbankingnews.com - May 5 at 1:15 PM
Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - May 5 at 11:13 AM
Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & CeTaysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Ce
us.acrofan.com - May 5 at 8:26 AM
Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell TherapyTaysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
finance.yahoo.com - May 5 at 8:26 AM
Taysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading VolumeTaysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading Volume
americanbankingnews.com - May 4 at 12:48 PM
Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11
finance.yahoo.com - May 4 at 9:57 AM
-$0.54 EPS Expected for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) This Quarter-$0.54 EPS Expected for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) This Quarter
americanbankingnews.com - May 3 at 6:46 PM
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.8%Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.8%
americanbankingnews.com - May 3 at 2:28 PM
Taysha Gene Therapies Inc (TSHA)Taysha Gene Therapies Inc (TSHA)
investing.com - April 29 at 5:50 PM
Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Chardan CapitalTaysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Chardan Capital
americanbankingnews.com - April 29 at 10:04 AM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.5%Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.5%
americanbankingnews.com - April 27 at 11:38 AM
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - April 23 at 6:50 AM
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 5.3%Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 5.3%
americanbankingnews.com - April 22 at 2:46 PM
DateCompanyBrokerageAction
3/26/2021Black Diamond TherapeuticsHC WainwrightReiterated Rating
1/19/2021Black Diamond TherapeuticsCanaccord GenuityReiterated Rating
1/6/2021Black Diamond TherapeuticsWedbushInitiated Coverage
11/24/2020Black Diamond TherapeuticsBerenberg BankInitiated Coverage
2/24/2020Black Diamond TherapeuticsCowenInitiated Coverage
2/24/2020Black Diamond TherapeuticsJefferies Financial GroupInitiated Coverage
2/24/2020Black Diamond TherapeuticsJPMorgan Chase & Co.Initiated Coverage
8/14/2020VaxcyteNeedham & Company LLCReiterated Rating
7/7/2020VaxcyteBank of AmericaInitiated Coverage
7/7/2020VaxcyteCantor FitzgeraldInitiated Coverage
1/28/2021Sutro BiopharmaTruistBoost Price Target
12/2/2020Sutro BiopharmaStifel NicolausInitiated Coverage
11/6/2020Sutro BiopharmaPiper SandlerBoost Price Target
7/16/2020Sutro BiopharmaWells Fargo & CompanyInitiated Coverage
5/12/2020Sutro BiopharmaB. RileyDowngrade
1/13/2020Sutro BiopharmaSunTrust BanksInitiated Coverage
10/7/2019Sutro BiopharmaBTIG ResearchInitiated Coverage
9/5/2019Sutro BiopharmaJMP SecuritiesReiterated Rating
7/18/2019Sutro BiopharmaDeutsche Bank AktiengesellschaftInitiated Coverage
5/13/2021TCR2 TherapeuticsMizuhoInitiated Coverage
3/17/2021TCR2 TherapeuticsSVB LeerinkLower Price Target
3/11/2021TCR2 TherapeuticsBMO Capital MarketsLower Price Target
11/30/2020TCR2 TherapeuticsRoth CapitalBoost Price Target
8/12/2020TCR2 TherapeuticsTruist FinancialInitiated Coverage
4/26/2021Taysha Gene TherapiesChardan CapitalReiterated Rating
4/19/2021Taysha Gene TherapiesMorgan StanleyBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
1/4/2021Taysha Gene TherapiesOppenheimerInitiated Coverage
10/19/2020Taysha Gene TherapiesThe Goldman Sachs GroupInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.